Zimmer Biomet (ZBH) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $17.67B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Ivan Tornos |
| IPO Date | 2001-07-25 | CAGR | 8.72% |
| Employees | 17,000 | Website | www.zimmerbiomet.com |
| Div. Yield | 0.27% | Payout Ratio | 25% |
| Buy Back Yield | 0.37% | Total Yield | 0.64% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $25.81B | P/E | 10.77 | Forward P/E | 10.15 | PEG | 0.69 |
| P/S | 8.34 | P/B | 4.74 | P/CF | 42.22 | P/FCF | 38.24 |
| Sales | $8.41B | Sales 1Y | 9.23% | Sales 3Y | 18.31% | Sales 5Y | 22.9% |
| EPS | $8.48 | EPS 1Y | -14.82% | EPS 3Y | 79.91% | EPS 5Y | 43.12% |
| Sales QoQ | -7% | EPS QoQ | 74.29% | Sales QoQ Avg | 2.57% | EPS QoQ Avg | 17.47% |
| Gross Margin | 70.03% | Operating Margin | 15.61% | Profit Margin | 9.05% | ROCE | 6.24% |
| ROA | 3% | ROE | 6% | Altman Z Score | 2.05 | Piotroski Score | 9 |
| Current Ratio | 2.94 | Quick Ratio | 1.61 | Cash Ratio | 0.25 | Op. CF Ratio | 0.21 |
| Debt/Equity | 0.51 | Debt/Assets | 0.33 | Lt Debt/Equity | 0.43 | Lt Debt/Cap. | 0.3 |
| Intrst Cov. | 4.44 | Inventory Turnover | 1.12 | Asset Turnover | 0.37 | Receivables Turnover | 4.86 |
| Enterprise Value | $25.81B | P/E Ratio | 10.77 |
| Forward P/E | 10.15 | PEG Ratio | 0.69 |
| P/S Ratio | 8.34 | P/B Ratio | 4.74 |
| P/CF Ratio | 42.22 | P/FCF Ratio | 38.24 |
| EPS | $8.48 | EPS Growth 1Y | -14.82% |
| EPS Growth 3Y | 79.91% | EPS Growth 5Y | 43.12% |
| Revenue Growth 1Y | 9.23% | Gross Margin | 0.7% |
| Operating Margin | 0.16% | Profit Margin | 0.09% |
| ROE | 0.06% | ROA | 0.03% |
| ROCE | 0.06% | Current Ratio | 2.94 |
| Quick Ratio | 1.61 | Cash Ratio | 0.25 |
| Debt/Equity | 0.51 | Interest Coverage | 4.44 |
| Altman Z Score | 2.05 | Piotroski Score | 9 |
Zimmer Biomet (ZBH) valuation & financials
Zimmer Biomet (ZBH) has a market capitalization of $17.67B and trades at a price-to-earnings ratio of 10.8. It operates in the Healthcare sector (Medical - Devices).
Zimmer Biomet's revenue grew +9.2% over the last year.
Zimmer Biomet's next earnings report is scheduled for August 5, 2026 before market open; analysts estimate EPS of $2.01.
Zimmer Biomet (ZBH) — frequently asked questions
When does Zimmer Biomet (ZBH) report earnings next?
Zimmer Biomet is expected to report earnings on August 5, 2026 before market open. Analysts estimate EPS of $2.01.
What is Zimmer Biomet's market cap?
Zimmer Biomet (ZBH) has a market capitalization of $17.67B.
What is ZBH's P/E ratio?
Zimmer Biomet trades at a price-to-earnings ratio of 10.8, with trailing twelve-month EPS of $8.48.
How fast is Zimmer Biomet growing?
Zimmer Biomet's revenue grew +9.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)